SELLAS Life Sciences Group
SELLAS Life Sciences Group is a biopharmaceutical company focused on developing novel cancer therapeutics, including the immunotherapeutic agent galinpepimut-S and the CDK9 inhibitor SLS009, targeting various hematological cancers and solid tumors.
Company Overview
SELLAS Life Sciences Group focuses on developing novel therapeutics for various cancer indications. With a strategic emphasis on immunotherapy and targeted cancer treatment, the company aims to address unmet medical needs in oncology.
Product Candidates
SELLAS Life Sciences Group's product candidates include galinpepimut-S (GPS) and SLS009. GPS is a cancer immunotherapeutic agent targeting the Wilms tumor 1 (WT1) protein, while SLS009 is a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor. These products are developed for the treatment of both hematological cancers and solid tumors.
Licensing and Collaborations
SELLAS has secured global licensing rights for galinpepimut-S from Memorial Sloan Kettering Cancer Center. SLS009 is licensed from GenFleet Therapeutics (Shanghai), Inc., for areas outside Greater China. These agreements support the company's development and commercialization of innovative cancer therapies.
Clinical Trials
SELLAS Life Sciences Group is actively conducting clinical trials for its product candidates. These trials include evaluations of GPS for Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM). For SLS009, clinical studies are being conducted in combination with venetoclax and azacytidine for relapsed/refractory AML.
Financing Initiatives
SELLAS has announced a $20 million registered direct offering and concurrent private placement, priced at-the-market under Nasdaq rules. This financing initiative aims to support the ongoing development and commercialization of its cancer therapy portfolio.